Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Arimoclomol Prospective Double-blind, Randomised, Placebo-controlled Study in Patients Diagnosed With Niemann-Pick Disease Type C

NCT02612129 is registered in ClinicalTrials.gov with ZevraDenmark as lead sponsor.

NCT NCT02612129
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02612129 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Arimoclomol Prospective Double-blind, Randomised, Placebo-controlled Study in Patients Diagnosed With Niemann-Pick Disease Type C
Lead sponsor
ZevraDenmark
Phase
Phase 2/3
Overall status
Completed
Start date
June 14, 2016
Completion date
October 31, 2024
Enrollment
50 (actual)
Sites
14

Conditions

As the registry lists them; a condition with its own page is linked.

niemann-pick disease, type c